Login to Your Account



Rigel Chasing Pfizer in RA; Nabs $1.2B-Plus AstraZeneca Alliance

By Jennifer Boggs


Wednesday, February 17, 2010
Armed with some big pharma muscle in the form of a potential $1 billion-plus deal with AstraZeneca plc, Rigel Pharmaceuticals Inc. is hot on Pfizer Inc.'s heels in the race for an oral, disease-modifying rheumatoid arthritis drug. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription